Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis.

Abstract

The results of a 2-year placebo-controlled study in 38 female patients with osteoporosis are presented. This study was conducted to evaluate the efficacy of a daily oral dose of 2.5 mg Org OD 14 ((7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) in the treatment of established osteoporosis. Org OD 14 is a steroid which shows combined weak oestrogenic, androgenic and progestational activity. A total of 31 patients completed a 12-month study period (17 placebo, 14 Org OD 14) and 25 of these went on to complete the full 24-months (15 placebo, 10 Org OD 14). A significant increase in bone mineral density as measured by dual photon absorptiometry was recorded in the lumbar spine in the Org OD 14-treated patients at 8, 16 and 24 months. The gain in bone mass after 8 months averaged 4% (P less than 0.01) and after 24 months 8% (P less than 0.001). In the control group, a bone loss rate of 2% per year was recorded in the lumbar spine. No significant changes in bone density in the forearm as assessed by single photon absorptiometry were found in either group. The increase in spinal bone density in the Org OD 14 group was non-linear and followed an S-shaped upward pattern. Org OD 14, while inducing no appreciable endometrial stimulation, was found to be a bone-active compound with anti-resorbing as well as anabolic activity. Org OD 14 warrants consideration not only for the long-term prevention of bone loss but also for curative treatment of post-menopausal osteoporosis.

• Authors: P Geusens, J Dequeker, J Gielen, L P Schot
• Journal: Maturitas (Maturitas) Vol. 13 Issue 2 Pg. 155-62 (Jun 1991) ISSN: 0378-5122 [Print] Ireland
• PMID: 1921738 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anabolic Agents
• Norpregnenes
• tibolone

Topics

• Absorptiometry, Photon
• Aged
• Anabolic Agents (therapeutic use)
• Bone Density (drug effects)
• Double-Blind Method
• Female
• Humans
• Norpregnenes (therapeutic use)
• Osteoporosis, Postmenopausal (diagnostic imaging, drug therapy, pathology)
• Radionuclide Imaging
• Spine (diagnostic imaging, pathology)